PE20142281A1 - Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio - Google Patents
Compuestos de cromano sustituidos como moduladores del receptor sensible al calcioInfo
- Publication number
- PE20142281A1 PE20142281A1 PE2014001297A PE2014001297A PE20142281A1 PE 20142281 A1 PE20142281 A1 PE 20142281A1 PE 2014001297 A PE2014001297 A PE 2014001297A PE 2014001297 A PE2014001297 A PE 2014001297A PE 20142281 A1 PE20142281 A1 PE 20142281A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- substituted
- calcium sensitive
- halogen
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) EN DONDE Ra ES H, HALOGENO, ALQUILO, ENTRE OTROS; Rb ES H, CICLOALQUILO, ALQUILO, ENTRE OTROS; R ES HALOGENO, HIDROXIALQUILO, ENTRE OTROS, X ES UN ENLACE -O-, -NR7-, ENTRE OTROS; Rc Y Rd SE SELECCIONAN INDEPENDIENTEMENTE DE H, HIDROXI, CIANO, ENTRE OTROS; Z ES -OR6, -NR10R11; R1 ES HALOGENO, NITRO, HALOALQUILO, ENTRE OTROS; R2 ES ARILO SUSTITUIDO, HETEROARILO SUSTITUIDO, ENTRE OTROS; R3 Y R4 SE SELECCIONAN INDEPENDIENTEMENTE DE H, HALOALQUILO, ALCOXI SUSTITUIDO ENTRE OTROS, R5 ES ALQUILO SUSTITUIDO ENTRE OTROS; R6 ES H, ALQUILO SUSTITUIDO, ALQUENILO SUSTITUIDO ENTRE OTROS, R7 ES H, ALQUILO, ALQUINILO, ENTRE OTROS; R10 Y R11 SE SELECCIONA DE FORMA INDEPENDIENTE DE H, ALQUILO, CICLOALQUILO, ENTRE OTROS; n es 1-3; m ES 0-3; p ES 0-4; q ES 0-3. SON COMPUESTOS PREFERIDOS METIL 2-FLUORO-5-((2R, 4R)-2-((((R)-1-(NAFTALEN-1-IL)ETIL)AMINO)METIL)CROMAN-4-IL)BENZOATO; 2-FLUORO-5-((2R, 4S)-2-((((R)-1-(NAFTALEN-1-IL)ETIL)AMINO)METIL)CROMAN-4-IL)BENZOATO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE LAS AFECCIONES ASOCIADOS CON LA MODULACION DE LOS RECEPTORES SENSIBLES AL CALCIO (CaSR).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN178KO2012 | 2012-02-24 | ||
| IN1030KO2012 | 2012-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142281A1 true PE20142281A1 (es) | 2015-01-16 |
Family
ID=54261188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001297A PE20142281A1 (es) | 2012-02-24 | 2013-02-22 | Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102041154B1 (ko) * | 2012-02-24 | 2019-11-07 | 루핀 리미티드 | 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 |
| AU2013308081A1 (en) * | 2012-08-27 | 2015-02-26 | Lupin Atlantis Holdings Sa | Arylalkylamine compounds as calcium sensing receptor modulators |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| US9493396B2 (en) | 2013-08-28 | 2016-11-15 | Lupin Atlantis Holdings Sa | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| CA3158696A1 (en) | 2019-11-19 | 2021-05-27 | Lupin Limited | Process for preparing chroman compounds |
| BR112022012663A2 (pt) | 2019-12-27 | 2022-09-06 | Lupin Ltd | Composição farmacêutica de moduladores de casr e métodos e usos da mesma |
| WO2021144814A1 (en) | 2020-01-17 | 2021-07-22 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0020018B1 (en) * | 1979-05-19 | 1983-06-01 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
| EP1630157A4 (en) | 2003-05-28 | 2007-05-23 | Japan Tobacco Inc | ANTAGONIST OF CASR |
| US7585886B2 (en) | 2005-05-19 | 2009-09-08 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| TW200815388A (en) | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| WO2008041118A2 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| MX2009003981A (es) * | 2006-10-26 | 2009-04-27 | Amgen Inc | Agentes moduladores del receptor de calcio. |
| US8153658B2 (en) | 2006-11-16 | 2012-04-10 | Astellas Pharma, Inc. | Piperidine derivative or salt thereof |
| ES2476391T3 (es) * | 2007-10-15 | 2014-07-14 | Amgen Inc. | Agentes moduladores de receptor de calcio |
| AU2008328362A1 (en) | 2007-11-23 | 2009-05-28 | Leo Pharma A/S | Novel cyclic hydrocarbon compounds for the treatment of diseases |
| CN102239136B (zh) | 2008-10-03 | 2014-09-17 | 味之素株式会社 | CaSR激动剂 |
| US8791147B2 (en) | 2008-10-08 | 2014-07-29 | Amgen Inc. | Calcium receptor modulating agents |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
| RU2013128973A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительных рецепторов |
| EP2643290A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| CN103228629A (zh) | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 作为CaSR活性化合物的被取代的环戊基-氮杂苯类 |
| US9382216B2 (en) | 2011-03-10 | 2016-07-05 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| AP2013007153A0 (en) | 2011-03-18 | 2013-09-30 | Lupin Ltd | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators |
| KR102041154B1 (ko) * | 2012-02-24 | 2019-11-07 | 루핀 리미티드 | 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 |
-
2013
- 2013-02-22 KR KR1020147025242A patent/KR102041154B1/ko active IP Right Grant
- 2013-02-22 GE GEAP201313579A patent/GEP20186911B/en unknown
- 2013-02-22 NZ NZ628627A patent/NZ628627A/en unknown
- 2013-02-22 PL PL13712928T patent/PL2817299T3/pl unknown
- 2013-02-22 UA UAA201410409A patent/UA112679C2/uk unknown
- 2013-02-22 RS RSP20191101 patent/RS59172B1/sr unknown
- 2013-02-22 JP JP2014558258A patent/JP6114316B2/ja active Active
- 2013-02-22 US US14/380,632 patent/US9163001B2/en active Active
- 2013-02-22 PE PE2014001297A patent/PE20142281A1/es active IP Right Grant
- 2013-02-22 MY MYPI2014702272A patent/MY171374A/en unknown
- 2013-02-22 MX MX2014010139A patent/MX355670B/es active IP Right Grant
- 2013-02-22 AP AP2014007919A patent/AP2014007919A0/xx unknown
- 2013-02-22 PT PT13712928T patent/PT2817299T/pt unknown
- 2013-02-22 CA CA2864332A patent/CA2864332C/en active Active
- 2013-02-22 ES ES13712928T patent/ES2743492T3/es active Active
- 2013-02-22 IN IN1672MUN2014 patent/IN2014MN01672A/en unknown
- 2013-02-22 SG SG11201405117SA patent/SG11201405117SA/en unknown
- 2013-02-22 WO PCT/IB2013/051445 patent/WO2013124828A1/en active Application Filing
- 2013-02-22 DK DK13712928.4T patent/DK2817299T3/da active
- 2013-02-22 EP EP13712928.4A patent/EP2817299B1/en active Active
- 2013-02-22 AU AU2013223715A patent/AU2013223715B2/en active Active
- 2013-02-22 HU HUE13712928A patent/HUE046172T2/hu unknown
- 2013-02-22 CN CN201380021510.0A patent/CN104350047B/zh active Active
- 2013-02-22 CU CUP2014000103A patent/CU24325B1/es unknown
- 2013-02-22 EA EA201491582A patent/EA026940B9/ru unknown
- 2013-02-22 SI SI201331561T patent/SI2817299T1/sl unknown
- 2013-02-22 BR BR112014021133-7A patent/BR112014021133B1/pt active IP Right Grant
- 2013-02-22 LT LTEP13712928.4T patent/LT2817299T/lt unknown
- 2013-02-23 TW TW102106358A patent/TWI617549B/zh not_active IP Right Cessation
- 2013-02-25 AR ARP130100556A patent/AR090135A1/es active IP Right Grant
-
2014
- 2014-08-14 TN TNP2014000352A patent/TN2014000352A1/fr unknown
- 2014-08-15 ZA ZA2014/05990A patent/ZA201405990B/en unknown
- 2014-08-20 PH PH12014501891A patent/PH12014501891B1/en unknown
- 2014-08-20 CL CL2014002218A patent/CL2014002218A1/es unknown
- 2014-08-21 NI NI201400094A patent/NI201400094A/es unknown
- 2014-08-21 IL IL234252A patent/IL234252A/en active IP Right Grant
- 2014-08-21 DO DO2014000193A patent/DOP2014000193A/es unknown
- 2014-08-22 GT GT201400179A patent/GT201400179A/es unknown
- 2014-09-10 MA MA37344A patent/MA35937B1/fr unknown
- 2014-09-17 CR CR20140424A patent/CR20140424A/es unknown
- 2014-09-23 CO CO14210706A patent/CO7160018A2/es unknown
-
2015
- 2015-06-16 HK HK15105709.4A patent/HK1205117A1/xx unknown
- 2015-09-01 US US14/842,141 patent/US9598391B2/en active Active
-
2017
- 2017-01-26 US US15/416,684 patent/US9987249B2/en active Active
-
2019
- 2019-09-05 HR HRP20191606 patent/HRP20191606T1/hr unknown
- 2019-09-10 CY CY20191100947T patent/CY1122017T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142281A1 (es) | Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| PE20142461A1 (es) | Moduladores del receptor de estrogeno y sus usos | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| PE20141678A1 (es) | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| PE20130647A1 (es) | Indoles | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| PE20150778A1 (es) | Moduladores de quinolinilo unidos a metileno de ror-gamma-t | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| EA201500557A1 (ru) | Антигельминтные соединения, композиции и способы их применения | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
| GT201500159A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| CY1120680T1 (el) | Ανταγωνιστες η3 που περιεχουν συνταξη πυρηνα φαινοξυπιπεριδινης | |
| EA201400854A1 (ru) | 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |